Inhibition of Neuronal Process Outgrowth and Neuronal Specific Gene Activation by the Brn-3b Transcription Factor*

(Received for publication, May 29, 1996, and in revised form, October 22, 1996)

Martin D. Smith , Sally J. Dawson and David S. Latchman Dagger

From the Medical Molecular Biology Unit, Department of Molecular Pathology, University College London Medical School, The Windeyer Building, Cleveland Street, London W1P 6DB, United Kingdom

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
Acknowledgment
REFERENCES


ABSTRACT

The differentiation of the ND7 neuronal cell line to a nondividing phenotype bearing numerous neurite processes is accompanied by a dramatic increase in the levels of the activating POU family transcription factor Brn-3a and a corresponding fall in the levels of the closely related inhibitory factor Brn-3b. We have previously shown that the artificial overexpression of Brn-3a in these cells can induce neurite outgrowth and the activation of genes encoding synaptic vesicle proteins in the absence of a differentiation-inducing stimulus. Here we show that overexpression of Brn-3b can reduce process outgrowth and synaptic vesicle gene expression following exposure to a stimulus which would normally induce differentiation. These inhibitory effects are abolished by altering a single amino acid in the POU homeodomain of Brn-3b to its equivalent in Brn-3a. The converse mutation in Brn-3a allows it to inhibit process outgrowth in response to a differentiation-inducing stimulus. Hence a single amino acid difference results in these closely related factors having opposite effects and allows the balance between them to regulate differentiation.


INTRODUCTION

The Brn-3a, Brn-3b, and Brn-3c transcription factors (also known as Brn-3.0, 3.2, and 3.1, respectively) (1, 2) are closely related members of the POU family of transcription factors which are encoded by three distinct genes (3, 4, 5, 6) (for review of POU factors see Refs. 7 and 8). Among the mammalian POU factors, the Brn-3 proteins are the most closely related to the nematode POU factor Unc-86, which plays a critical role in neuronal development in the nematode (9, 10) suggesting that the Brn-3 factors may play a similar role in mammals. In agreement with this idea the three members of the Brn-3 family are expressed in distinct but overlapping populations of neuronal cells during development and in the adult organism (1, 2, 3, 4, 5, 11) with Brn-3a for example being expressed in the first differentiated neurons to appear in the midbrain, hindbrain, and spinal cord during development (12). Interestingly Brn-3a has been shown in co-transfection experiments to activate several promoters including those of the neuronally expressed genes encoding pro-opiomelancortin (1), alpha -internexin (13), and the presynaptic vesicle protein SNAP-25 (14) as well as a thymidine kinase (tk)1 promoter containing an added synthetic binding site for the various forms of Brn-3 (tk-Oct) (15, 18). In contrast Brn-3b represses these promoters (13, 15, 18) and also inhibits their activation by Brn-3a. Similarly Brn-3c has only a weak activating effect on these promoters (13, 15, 18).

When the proliferating ND7 cell line (obtained by fusing primary dorsal root ganglion neurons with C1300 neuroblastoma cells) (17) is induced to cease dividing and differentiate to a mature neuronal-like phenotype by treatment with cyclic AMP or removal of serum from the medium (18), the levels of Brn-3a rise dramatically, and those of Brn-3b fall (3, 15), while Brn-3c levels remain unchanged.2 This differentiation process is likely to require the induction of specific genes involved in the outgrowth of neurite processes and the acquisition of a more neuronal-like phenotype. If such genes were targets for activation by Brn-3a and repression by Brn-3b, the changes in Brn-3 expression could potentially play a key role in the differentiation process by activating the expression of such genes. Hence the ND7 cell system offers a convenient model system for studying the role of the Brn-3 factors in neuronal differentiation.

Indeed we have previously used this system to show that the inhibition of Brn-3a expression using an antisense approach prevents the neurite outgrowth and elevated expression of SNAP-25, which normally occur following exposure of ND7 cells to a differentiation inducing stimulus (14). Moreover, the stable overexpression of Brn-3a in ND7 cell clones resulted in neurite outgrowth and the induction of several synaptic proteins including SNAP-25 even in the absence of a differentiation inducing stimulus (19).

Given the ability of Brn-3a to induce the SNAP-25 promoter in co-transfection experiments (14), it is therefore likely that the rise in Brn-3a, which occurs during ND7 cell differentiation, directly activates the SNAP-25 promoter and is thus responsible for the rise in SNAP-25 expression, which occurs during the differentiation event. Moreover, the finding that SNAP-25 expression is essential for neurite outgrowth in several different types of neuronal cells in vitro and in vivo (20) indicates that the exocytosis of synaptic vesicles, which is required for synaptic transmission, and the constitutive exocytosis, which is required for axon outgrowth, may have several components such as SNAP-25 in common. Hence, the induction by Brn-3a of SNAP-25 gene expression and that of other synaptic proteins is likely to be responsible, at least in part, for its ability to induce neurite outgrowth.

Although these findings indicate a critical role for the rise in Brn-3a expression in inducing neuronal differentiation in ND7 cells, they also focus attention on the role of Brn-3b. Thus the levels of Brn-3b fall dramatically during ND7 cell differentiation (3, 15), while in co-transfection experiments it both represses the basal activity of a number of different promoters, which are activated by Brn-3a, and prevents their activation by Brn-3a (13, 15, 16). We have therefore investigated the response of ND7 cell clones overexpressing Brn-3b to a stimulus which would normally induce differentiation and have compared this to the response of clones overexpressing either Brn-3a or Brn-3c.


MATERIALS AND METHODS

Preparation of Cell Lines and Analysis of Brn-3 Expression

cDNA clones of wild type and mutant forms of Brn-3a, Brn-3b, and Brn-3c, as well as the POU domains of Brn-3a and Brn-3b, were inserted in the sense orientation under the control of the dexamethasone-inducible mouse mammary tumor virus (MMTV) promoter of the mammalian expression vector PJ5 (21). Following co-transfection into ND7 cells (17) together with a plasmid conferring neomycin resistance (pM5G-NEO), stable transfectants were selected by the supplementation of culture medium with G418 to a final concentration of 800 µg/ml, and individual clones were isolated after 7-14 days of selection. Putative clones were treated with dexamethasone at a final concentration of 1 µM for 24 h to induce expression of the MMTV promoter to allow screening for clones capable of expressing the exogenous construct. RNA was isolated from cells by the guanidinium thiocyanate method (22), treated with DNase to remove any contaminating DNA, and subsequently used as the template for cDNA synthesis. Resultant cDNA was amplified by PCR essentially as described by Kawasaki (23). In initial screening experiments to confirm that exogenous constructs were producing sense mRNAs in the cell lines, PCR was performed using a forward primer internal to the POU domain (Brn-3a, 5'-GACTCGGACACGGACCCCGCG-3'; Brn-3b, 5'-GACGTGGATGCAGACCCGCGG-3'; Brn-3c, 5'-GATGTGGAGTCAGACCCTCGA-3') and a reverse primer internal to the vector sequence (5'-AGATCTGGTACCATCGAT-3') so as not to amplify endogenous Brn-3mRNA, with product detected by Southern hybridization with homologous probes. cDNA from clones capable of expressing the exogenous construct were subsequently subjected to PCR to determine the total level of expression of that member of the Brn-3 family by using forward and reverse primers internal to the POU domain thus amplifying both exogenous and endogenous mRNAs (Forward primers as above. Reverse primers: Brn-3a, 5'-CCCTCCTCAGTAAGTGGC-3'; Brn-3b, 5'-CTAAATGCCGGCAGAGTATTTCAC-3'; Brn-3c, 5'-CAATCGTCCACAGCAGAGTATTT-3'). Sample pairs were equalized using primers designed to amplify the mRNA species encoding the invariant L6 ribosomal protein (5'-ATCGCTCCTCAAACTTGACC-3' and 5'-AACTACAACCACCTCATGAA-3'). In all cases expression was studied in the presence or absence of dexamethasone in cells either proliferating in full serum-containing medium or induced to differentiate by growth in serum-free medium.

Analysis of Neurite Outgrowth

In all cases cultures differentiated in the absence of dexamethasone were analyzed in parallel with dexamethasone-induced experimental differentiated cultures, and both subsequently compared to lines expressing the PJ5 vector with an empty expression cassette induced to differentiate in the presence or absence of dexamethasone. To determine neurite process length cells were subject to immunocytochemistry using a primary monoclonal antibody to alpha -tubulin detected by the peroxidase/diaminobenzidene color reaction. The length of the longest process in each of 400 cells was determined for each sample using video capture NIH Image software (version 1.59) with the operator unaware of the nature of the sample. Statistical analysis was performed using Microstat software to compare the means of triplicate determinations. In all cases the paired t test was used to compare different cell lines either before or after steroid treatment while the Mann Whitney test was used to compare data in a single set of cell lines before and after steroid treatment.

Measurement of RNA Levels

cDNAs were first subject to PCR designed to amplify the mRNA species encoding the L6 ribosomal proteins (see above). Following subsequent Southern hybridization to allow the equalization of cDNA input between both uninduced and induced control and experimental samples, PCR amplification using primers to specifically amplify the mRNA species encoding SNAP25 (5'-TGACCAGCTGGCTGATGAGTC-3' and 5'-CCCATGTCTAGGGGGCCATATGA-3') and GAP43 (5'-GTGCTCTGGTTTCCTTAGCA-3' and 5'-GATATAGCCCTCATCCATCA-3') was performed. Similar amplifications were also performed, using primers designed to specifically amplify synapsin Ia (5'-ATGGAGACTACCGCAGTTTG-3' and 5'-CACAACTACAGGGTATGTTG-3), synaptotagmin I (5'-TCGCCCATGGCTGTGGTTGCT-3' and 5'-CTGGAAATCATAGTCCAGAG-3') and synaptophysin I (5'-CAGAAACAAGTACCGAGAA-3' and 5'-CCAAACACCACTGAGGTGTT-3'). All amplifications were carried out using levels of mRNA and numbers of cycles, which had been shown in previous control experiments to give levels of product that were linearly related to the amount of input RNA (data not shown). Following amplification, products were run on agarose gels and hybridized with appropriate probes for each amplification product.

Growth Measurements

The cell doubling rate of experiment and control cultures in serum-free medium was determined, allowing the construction of growth curves, while the S-phase proliferative fraction of each culture was determined by bromodeoxyuridine (BrdUrd) incorporation and subsequent immunocytochmical detection using a BrdUrd labeling and detection kit (Boehringer Mannheim) according to the manufacturer's instructions. The number of positive nuclei in a population of 500 cells per sample was determined for the purpose of statistical analysis.


RESULTS

When ND7 cells are induced to differentiate by removal of serum, the level of Brn-3a rises and that of Brn-3b falls (Fig. 1a). To test the effect of Brn-3b on the differentiation of ND7 cells we used cell lines prepared by stably transfecting ND7 cell lines with cDNA clones for Brn-3a, Brn-3b or Brn-3c under the control of the dexamethasone inducible MMTV promoter, allowing us to regulate the level of Brn-3 in each cell line by steroid treatment. Three cell lines of each type selected on the basis of their neomycin resistance (encoded on a co-transfected plasmid) were used to control for clonal variation.


Fig. 1. a, levels of endogenous Brn-3a and Brn-3b mRNA expressed in parental ND7 cells both in the presence (+) and absence (-) of serum as assayed by reverse transcriptase-PCR. b, Reverse transcriptase-PCR amplification of mRNA in a representative cell line overexpressing Brn-3a (left panel) and in similar cell lines overexpressing Brn-3b (center panel), or Brn-3c (right panel). In each case the top row shows the amplification of the RNA expressed from the exogenous transfected gene for either Brn-3a (left panel), Brn-3b (center panel), or Brn-3c (right panel). The central row shows the amplification of the exogenous and endogenous mRNAs for either Brn-3a (left panel), Brn-3b (center panel), or Brn-3c (right panel), and the bottom row shows amplification of the control mRNA encoding the L6 ribosomal protein. Samples were prepared as indicated from samples grown in the absence or presence of dexamethasone to induce exogenous gene expression and in the presence or absence of serum to induce differentiation.
[View Larger Version of this Image (33K GIF file)]


Each showed basal and steroid inducible expression of the appropriate transfected form of Brn-3 in cells proliferating in full-serum containing medium as assayed by PCR using one primer specific for the RNA transcript derived from a transfected plasmid and one primer specific for the appropriate form of Brn-3 (Fig. 1b). Similarly increased basal levels and steroid inducibility of each form of Brn-3 in the proliferating cells could be demonstrated by PCR using primers which would specifically amplify both the endogenous and exogenous mRNAs encoding each form of Brn-3 (Fig. 1b). Most importantly the levels of the exogenous Brn-3 in each cell line were unaffected by the induction of cell differentiation by removal of serum. Thus the fall in endogenous Brn-3b that occurs in these circumstances (see Fig. 1a) in all the cells resulted in the Brn-3b-transfected cells having a much higher level of Brn-3b than control cells following exposure to a differentiation-inducing stimulus (Fig. 1b). Moreover, the differentiated Brn-3a-transfected cells still maintained a higher total level of Brn-3a than control cells (Fig. 1b) despite the rise in endogenous Brn-3a levels that occurs upon differentiation (see Fig. 1a) (3, 15). Similarly, enhanced levels of Brn-3c were also observed in the Brn-3c transfected cells (Fig. 1b).

We therefore investigated the effect of Brn-3a, Brn-3b, or Brn-3c over expression on the outgrowth of neurites which normally occurs following removal of serum from the ND7 cells (18). Cells were induced to differentiate by removal of serum and the effect of each form of Brn-3 assessed. As shown in Fig. 2 and Table I the Brn-3a- and Brn-3c-expressing cell lines exhibited enhanced neurite length compared to control cells following the induction of differentiation and exposure to steroid treatment to fully induce expression of Brn-3a or Brn-3c (p < 0.05 for Brn-3a or Brn-3c cell lines compared to vector, in a paired t test). This extends our previous conclusion (19) that Brn-3a and to a lesser extent Brn-3c can induce neurite outgrowth even in full serum-containing medium and indicates that exogenous Brn-3a can enhance outgrowth even in the presence of the enhanced levels of endogenous Brn-3a produced by the differentiation-inducing stimulus.


Fig. 2. Effect of overexpressing the indicated form of Brn-3 on process formation. Panel a, typical fields of differentiated cells induced with dexamethasone showing cells transfected with vector (i) and cells overexpressing Brn-3a (ii) or Brn-3b (iii). Panels b and c, quantitative data on the length of the processes (panel b) and proportion of cells with processes (panel c) following exposure to serum-free medium. In each case, the values are shown for three independent clones overexpressing each construct and are compared to the level observed in ND7 cells transfected with vector alone (PJ5). Shaded bars, uninduced promoter; solid bars, dexamethasone-induced promoter. Values are the means of two independent experiments, each analyzed in duplicate, the error bars indicate the standard deviation of the mean.
[View Larger Version of this Image (49K GIF file)]


Table I.

Neurite length in cell lines expressing different forms of Brn-3

In all cases values are the mean ± the standard error of the mean obtained in triplicate determinations of neurite length in each of three different clonal cell lines of each type.
Brn-3 isoform Average neurite length when differentiated in the absence of dexamethasone Average neurite length when differentiated in the presence of dexamethasone

µm
Control vector 55  ± 9 58.6  ± 13
Brn-3a 62  ± 10 72.7  ± 15
Brn-3b 46  ± 2 36  ± 11
Brn-3c 49  ± 13 71  ± 9

In contrast however, all three Brn-3b-expressing cell lines showed decreased levels of neurite outgrowth compared to control cells following induction of differentiation even without steroid treatment (Fig. 2 and Table I, p < 0.001 in a paired t test). Following steroid treatment, these cells showed a further reduction in neurite length which was significant both in comparison to the neurite length observed in these cells in the absence of steroid treatment (p < 0.01 in a Mann Whitney test) and by comparison to the neurite length in similarly treated control cells (p < 0.01 in a paired t test) (Fig. 2b and Table I). This resulted in these processes being considerably shorter than those formed by control cells transfected with the pJ5 vector without any insert or those transfected with Brn-3a or Brn-3c. Hence the overexpression of Brn-3b can indeed interfere with neurite outgrowth following exposure of ND7 cells to a differentiation inducing stimulus. Interestingly overexpression of Brn-3a, Brn-3b, or Brn-3c had no effect on the numbers of cells bearing processes (Fig. 2c) indicating that Brn-3b acts by inhibiting the extension of the processes rather than their initial formation. In the case of Brn-3a, this effect is in contrast to its ability to enhance the number of processes formed in the absence of a differentiation inducing stimulus. This indicates that the rise in endogenous Brn-3a levels which occurs upon differentiation is sufficient for maximal numbers of processes to form so that further overexpression of Brn-3a enhances only the length of the processes which form (14, 19).

When ND7 cells are differentiated by transfer to serum-free medium, process outgrowth is accompanied by a cessation of cell division (17, 18), although this latter effect is not observed in Brn-3a-overexpressing cells growing in serum-containing medium (19). We therefore investigated the effect of overexpressing each of the forms of Brn-3 upon the growth arrest normally caused by serum removal. No significant alteration in either the growth rate (Fig. 3a) or in the proportion of cells in S phase as assayed by incorporation of bromodeoxyuridine (Fig. 3b) was observed in differentiated cells overexpressing Brn-3b. Thus, like overexpression of Brn-3a in undifferentiated cells, the overexpression of Brn-3b in differentiated cells has a much larger effect on neurite outgrowth than upon growth rate.


Fig. 3. Effect of overexpressing the indicated form of Brn-3 on growth rate (panel a) and the number of cells in S phase (panel b), in cells growing in serum-free medium. Shaded bars, uninduced promoter; solid bars, dexamethasone-induced promoter. Values are the means of two independent experiments, each analyzed in duplicate. The bar indicates the standard deviation of the mean. Data of three individual clones have been combined.
[View Larger Version of this Image (22K GIF file)]


We have shown that the induction of differentiation by Brn-3a is accompanied by the enhanced expression of four components of the synaptic vesicle cycle SNAP-25, synapsin I, synaptophysin, and synaptotagmin each of which plays a distinct role in different stages of the cycle (for review, see Refs. 24 and 25). Similarly, differentiation of ND7 cells by serum removal results in enhanced expression of these proteins (Fig. 4a). We therefore measured the expression of the mRNAs encoding each of these proteins when the ND7 cell lines expressing each of the forms of Brn-3 were induced to differentiate.


Fig. 4. a, basal level expression of the mRNAs encoding SNAP25, GAP43, synapsin I, synaptotagmin, and synaptophysin in proliferating (lane 1) and differentiated (lane 2) parental ND7 cell line assayed by reverse transcriptase-PCR. cDNA input was equalized on levels of expression of L6 ribosomal mRNA. b, levels of SNAP-25, GAP43, synapsin I, synaptotagmin, and synaptophysin in the various cell lines overexpressing different forms of Brn-3 growing in serum-free medium compared to that in ND7 cells transfected with pJ5 vector alone. Lane 1, pJ5 vector cells in the absence of dexamethasone induction; lane 2, pJ5 vector cells induced with dexamethasone; lane 3, Brn-3a-overexpressing cells without dexamethasone; lane 4, Brn-3a-overexpressing cells induced with dexamethasone; lane 5, Brn-3b-overexpressing cells without dexamethasone; lane 6, Brn-3b-overexpressing cells induced with dexamethasone.
[View Larger Version of this Image (19K GIF file)]


As shown in Fig. 4b, the Brn-3b-expressing cells showed reduced levels of SNAP-25, synaptotagmin and synaptophysin mRNAs following differentiation and steroid induction of Brn-3b expression, compared to the levels in similarly treated cells transfected with vector or Brn-3a (Fig. 4b). This was confirmed by statistical analysis of quantitative data on mRNA levels obtained by densitometric scanning of the autoradiographs (p < 0.05 comparing mRNA levels in the Brn-3b cells following differentiation and steroid induction with that in similarly treated control cells). Thus Brn-3b overexpression can indeed inhibit some of the genes normally induced during Brn-3a-induced differentiation. However, the levels of synapsin I mRNA were elevated in the differentiated Brn-3b-expressing cells compared to the control cells (Fig. 4b). This elevation in synapsin I expression is consistent with our recent co-transfection experiments which identified the synapsin I promoter as the first promoter that is inducible by all three forms of Brn-3 (26). As expected no change in GAP43 expression was noted in the Brn-3b-expressing cells (Fig. 4b), paralleling our previous findings that neither Brn-3a or Brn-3b alter the level of this protein in undifferentiated ND7 cells or regulate its promoter in co-transfections (19).

Hence as well as reducing the length of neurite processes, which form upon differentiation, Brn-3b can also inhibit some but not all of the changes in gene expression that occur during this process. In previous experiments, using chimeric proteins containing different regions of Brn-3a or Brn-3b, we have shown that the POU domain plays a key role in the different effects of these factors on target promoters in co-transfection assays (15, 16). Thus, although the POU domain of both factors can bind to DNA (5, 27), only the isolated POU domain of Brn-3a can activate the tk-Oct promoter (13), whereas the POU domain of Brn-3b cannot do so. Hence as well as acting as the DNA binding domain, the POU domain of Brn-3a can also act as a distinct activation domain. We therefore prepared ND7 cell lines overexpressing the isolated POU domain of Brn-3a or Brn-3b and tested their effect on neurite outgrowth. As shown in Fig. 5 the differentiated cells expressing the Brn-3a POU domain showed a similar enhancement of neurite length compared to control cells as did those expressing full-length Brn-3a (p < 0.05 in a paired t test comparing Brn-3a POU domain cells with controls). Moreover, the differentiated cells expressing the POU domain of Brn-3b showed a similar steroid inducible reduction in neurite length as occurred in cells expressing full-length Brn-3b (p < 0.01 in a paired t test comparing Brn-3b POU domain cells with controls). As expected no effects on the number of processes formed were observed in the cells overexpressing the POU domain paralleling the lack of effect of the full-length factors in differentiated cells (Fig. 6).


Fig. 5. Effect of overexpressing the indicated form of Brn-3 on the length of neurite processes which form in serum-free medium. Brn-3a I indicates the result with Brn-3a in which position 22 in the homeodomain has been changed from valine to isoleucine while Brn-3b V shows the result with Brn-3b containing the reciprocal mutation. Shaded bars, uninduced; solid bars, induced. Values are the average of that obtained from two independent experiments, each analyzed in duplicate. Data of three individual clones expressing each construct have been combined. The error bars show the standard deviation of the mean.
[View Larger Version of this Image (34K GIF file)]



Fig. 6. Effect of overexpressing the indicated form of Brn-3 on the proportion of cells with processes when grown in serum-free medium. Shaded bars, uninduced; solid bars, induced. Values are the average of two independent experiments each analyzed in duplicate and compared to the level in cells transfected with pJ5 vector alone. Data of three independent clones expressing each construct have been combined. The error bars show the standard deviation of the mean.
[View Larger Version of this Image (36K GIF file)]


Interestingly, as well as affecting neurite length in a similar fashion to the full-length protein, the POU domains also either enhanced (Brn-3a) or reduced (Brn-3b) the expression of SNAP-25 in a manner similar to that observed in differentiated cells overexpressing the full-length protein (Fig. 7). Hence the Brn-3b POU domain appears to be able to inhibit process outgrowth and SNAP-25 expression, whereas the Brn-3a POU domain has the opposite effect.


Fig. 7. Effect of overexpressing the indicated form of Brn-3 on SNAP-25 mRNA levels in cells grown in serum-free medium compared to those observed in similarly treated ND7 cells transfected with pJ5 vector alone. Shaded bars, uninduced; solid bars, induced. Values are the mean of that obtained from two independent preparations, each analyzed in duplicate. Data of three individual clones expressing each construct have been combined. The error bars show the standard deviation of the mean.
[View Larger Version of this Image (34K GIF file)]


This indicates that one or more of the seven amino acid differences between the POU domains of Brn-3a and Brn-3b (3, 16) plays a critical role in this effect. Six of these differences are in the relatively nonconserved linker region joining the POU-specific and POU homeodomains, which together make up the POU domain (7, 8). We have therefore focused our attention on the single difference in the POU homeodomain at position 22 and have shown that this plays a critical role in the different effects of Brn-3a and Brn-3b on a target promoter in co-transfection assays. Thus alteration of the isoleucine at this position in Brn-3b to the valine found in Brn-3a allows the mutant Brn-3b to activate the tk-Oct promoter (28).

We therefore tested the effect of overexpressing mutant forms of full-length Brn-3a or Brn-3b in which the amino acid at this position has been mutated to its equivalent in the other factor. In these experiments, mutant Brn-3b with valine instead of isoleucine at this position failed to inhibit neurite outgrowth (Fig. 5) in the differentiated cells compared to the levels observed in control differentiated cells. Hence the mutation of a single amino acid in Brn-3b results in its losing the ability to inhibit neurite outgrowth (p < 0.05 for Brn-3b valine compared to wild type Brn-3b in a paired t test). Similarly, the mutant Brn-3b also failed to inhibit SNAP-25 expression in the differentiated cells (Fig. 7).

Moreover, cells expressing Brn-3a with isoleucine instead of valine at position 22 showed a much smaller enhancement of SNAP-25 expression than did cells expressing intact Brn-3a (Fig. 7). More dramatically, these cells not only failed to show the enhancement of process formation characteristic of Brn-3a but actually showed a steroid-inducible reduction in process formation compared to control differentiated cells which was almost as large as that observed in cells expressing Brn-3b (Fig. 5). Thus the mutant Brn-3a isoleucine shows a dramatically different effect on neurite outgrowth compared to wild type Brn-3a (p < 0.01 for Brn-3a isoleucine compared to Brn-3a in a paired t test). Hence alterations at a single amino acid can dramatically affect the ability of Brn-3a or Brn-3b to regulate ND7 cell differentiation.


DISCUSSION

Our previous studies (14, 19) have shown that the overexpression of Brn-3a can enhance both the number and length of neurite processes, which form in ND7 cells under conditions that do not normally promote differentiation, and can also activate the expression of several genes encoding proteins involved in the synaptic vesicle cycle. The differentiation process in ND7 cells, however, normally involves both a rise in the level of Brn-3a and a fall in the level of Brn-3b (3, 15). In the experiments reported here we have investigated the role of Brn-3b in this process and have shown that, under conditions which normally promote differentiation, overexpression of Brn-3b can reduce the length of the neurites that form and reduce the expression of some but not all of the genes that are activated during Brn-3a-induced differentiation.

These findings indicate therefore that regulation of ND7 cell differentiation involves a balance between the differentiation-inducing factor Brn-3a and the inhibitory factor Brn-3b. As Brn-3a and Brn-3b are expressed in distinct but overlapping patterns in the developing and adult nervous system (1, 2, 3, 5, 11, 12), it is possible that they play a similar role in regulating neurite outgrowth during development and in response to nerve injury in the adult.

Although further studies will be required to confirm this possibility, our findings clearly establish Brn-3b as the first transcription factor to have an inhibitory effect on neurite outgrowth. Our recent identification of the gene encoding the neuronal nicotinic acetylcholine receptor alpha 2 subunit as the first example of a gene whose promoter is activated by Brn-3b and not Brn-3a (29, 30) raises the possibility that Brn-3b might inhibit neurite outgrowth by activating the expression of other genes whose products play a directly inhibitory role in outgrowth.

However, it is more likely that the inhibitory effect of Brn-3b is brought about by its ability to repress the activity of specific genes. Thus in co-transfection experiments we have previously shown that Brn-3b can repress the basal activity of several different promoters, which are inducible by Brn-3a, and can also interfere with their activation by Brn-3a (13, 15, 16). Moreover, in the experiments reported here the inhibition of neurite outgrowth was accompanied by a reduction in SNAP-25, synaptophysin, and synaptotagmin expression in the Brn-3b-overexpressing cells.

The ability of Brn-3b to prevent the rise in SNAP-25 expression which normally occurs during ND7 cell differentiation is of particular interest since this presynaptic vesicle protein (31) has itself been shown to be necessary for process formation by different neuronal cell types both in vitro and in vivo (20). It is likely therefore that the ability to inhibit the expression of SNAP-25 and potentially of other genes whose protein products are involved in the process of neurite outgrowth underlies the inhibitory effect of Brn-3b on process formation.

This association of the inhibitory effect of Brn-3b on specific gene expression and on neurite outgrowth is further supported by the critical role of the amino acid at position 22 in the homeodomain in this process. Thus alteration of the isoleucine at this position to the valine in Brn-3b prevents the inhibitory effect of Brn-3b not only on a co-transfected promoter (28) but also, as shown here, on endogenous SNAP-25 expression and on neurite outgrowth. Moreover, the reciprocal substitution in Brn-3a not only abolishes its ability to enhance neurite outgrowth but actually allows it to inhibit neurite outgrowth during differentiation.

We previously suggested (28) that Brn-3b may inhibit Brn-3a-induced genes simply by binding to the DNA and being unable to activate transcription. It would therefore passively inhibit gene expression by preventing Brn-3a from binding to the DNA. In this model position 22 in the homeodomain which is known to have no effect on DNA binding (28) would be involved in allowing Brn-3a to act as an activator perhaps by allowing Brn-3a to recruit a second activating factor (for further discussion, see Dawson et al. (28)), while Brn-3b could not do so. However, the finding that mutation of this position in Brn-3a allows it to actually inhibit neurite outgrowth suggests that Brn-3b (and the mutant Brn-3a) may actually act as an active repressor by interacting with wild type Brn-3a or the basal transcriptional complex (for discussion of the mechanisms of transcriptional repression see Refs. 32 and 33). In this case isoleucine at this position would allow this inhibitory interaction to occur, whereas valine would not do so.

Whatever the precise mechanism of this effect, however, it is already clear that Brn-3b is the first example of a transcription factor which can inhibit neurite outgrowth. The further analysis of this factor and its interaction with Brn-3a should greatly enhance our understanding of the mechanisms that regulate neurite outgrowth in development and may potentially have therapeutic implications for the treatment of human spinal injury when nerve regeneration is very poor.


FOOTNOTES

*   This work was supported by the Cancer Research Campaign and the Medical Research Council. The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Dagger    To whom correspondence should be addressed. Tel.: 0171-380-9343; Fax: 0171-387-3310; E-mail: j.wenley{at}ucl.ac.uk.
1    The abbreviations used are: tk, thymidine kinase; MMTV, mouse mammary tumor virus; PCR, polymerase chain reaction.
2    D. S. Latchman, unpublished data.

Acknowledgment

We thank Tarik Moroy for the gift of Brn-3 cDNA clones.


REFERENCES

  1. Gerrero, M. R., McEvilly, R. J., Tuner, E., Lin, C. R., O'Connell, S., Jenne, K. J., Hobbs, M. V., and Rosenfeld, M. G. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 10841-10845 [Abstract]
  2. Turner, E. E., Jenne, K. J., and Rosenfeld, M. G. (1994) Neuron 12, 205-218 [Medline] [Order article via Infotrieve]
  3. Lillycrop, K. A., Budhram-Mahadeo, V. S., Lakin, N. D., Terrenghi, G., Wood, J. N., Polak, J. M., and Latchman, D. S. (1992) Nucleic Acids Res. 20, 5093-5096 [Abstract]
  4. Ninkina, N. N., Stevens, G. E. M., Wood, J. N., and Richardson, W. D. (1993) Nucleic Acids Res. 21, 3175-3182 [Abstract]
  5. Theil, T., McLean-Hunter, S., Zornig, M., and Möröy, T. (1993) Nucleic Acids Res. 21, 5921-5929 [Abstract]
  6. Theil, T., Zechner, U., Klett, C., Adolph, S., and Möröy, T. (1994) Cytogenet. Cell Genet. 66, 267-271 [Medline] [Order article via Infotrieve]
  7. Verrijzer, C. P., Chen, J.-L., Yokomori, K., and Tjian, R. (1995) Cell 81, 1115-1125 [Medline] [Order article via Infotrieve]
  8. Wegner, M., Drolet, D. W., and Rosenfeld, M. G. (1993) Current Opin. Dev. Biol. 5, 488-498
  9. Desai, C., Garriga, G., McIntire, S. L., and Horvitz, H. R. (1988) Nature 336, 638-646 [CrossRef][Medline] [Order article via Infotrieve]
  10. Finney, M., Ruvkin, G., and Horvitz, H. R. (1988) Cell 55, 757-769 [Medline] [Order article via Infotrieve]
  11. He, X., Treacy, M. N., Simmons, D. M., Ingraham, H. A., Swanson, L. S., and Rosenfeld, M. G. (1989) Nature 340, 35-42 [CrossRef][Medline] [Order article via Infotrieve]
  12. Fedtsova, N. G., and Turner, E. E. (1996) Mech. Dev. 53, 291-304 [CrossRef]
  13. Budhram-Mahadeo, V. S., Morris, P. J., Lakin, N. D., Theil, T., Ching, G. Y., Lillycrop, K. A., Möröy, T., Liem, R. K. H., and Latchman, D. S. (1995) J. Biol. Chem. 270, 2853-2858 [Abstract/Free Full Text]
  14. Lakin, N. D., Morris, P. J., Theil, T., Sato, T. N., Moroy, T., Wilson, M. C., and Latchman, D. S. (1995) J. Biol. Chem. 270, 15858-15863 [Abstract/Free Full Text]
  15. Budhram-Mahadeo, V. S., Theil, T., Morris, P. J., Lillycrop, K. A., Möröy, T., and Latchman, D. S. (1994) Nucleic Acids Res. 22, 3092-3098 [Abstract]
  16. Morris, P. J., Theil, T., Ring, C. J. A., Lillycrop, K. A., Möröy, T., and Latchman, D. S. (1994) Mol. Cell. Biol. 14, 6907-6914 [Abstract]
  17. Wood, J. N., Bevan, S. J., Coote, P., Darn, P. M., Hogan, P., Latchman, D. S., Morrison, C., Rougon, G., Theveniau, M., and Wheatley, S. C. (1990) Proc. R. Soc. Lond. Ser. B 241, 187-194 [Medline] [Order article via Infotrieve]
  18. Suburo, A. M., Wheatley, S. C., Horn, D. A., Gibson, S. J., Jahn, R., Fischer-Colbrie, R., Wood, J. W., Latchman, D. S., and Polak, J. M. (1992) Neuroscience 46, 881-889 [Medline] [Order article via Infotrieve]
  19. Smith, M. D., Dawson, S. J., and Latchman, D. S. (1996) Mol. Cell. Biol., in press
  20. Osen-Sand, A., Catsicas, M., Staple, J. K., Jones, K. A., Ayala, G., Knowles, J., Grenningloh, G., and Catsicas, S. (1993) Nature 364, 445-448 [CrossRef][Medline] [Order article via Infotrieve]
  21. Morgenstern, J. P., and Land, H. (1990) Nucleic Acids Res. 18, 1068 [Medline] [Order article via Infotrieve]
  22. Chirgwin, J. M., Przybyla, A. E., MacDonald, R. J., and Rutter, W. J. (1979) Biochemistry 18, 5294-5299 [Medline] [Order article via Infotrieve]
  23. Kawasaki, E. S. (1990) in PCR Protocols (Innis, M. A., Gelfard, D. H., Sninsky, J. J., and White, T. J., eds), pp. 21-27, Academic Press, San Diego, CA
  24. Sudhof, T. C. (1995) Nature 375, 645-6535 [CrossRef][Medline] [Order article via Infotrieve]
  25. Sudhof, T. C., and Jahn, R. (1991) Neuron 6, 665-677 [Medline] [Order article via Infotrieve]
  26. Morris, P. J., Lakin, D. D., Dawson, S. J., Ryabanin, A. E., Kilimann, M. W., Wilson, M. C., and Latchman, D. S. (1996) Mol. Brain Res., in press
  27. Dawson, S. J., Liu, Y-Z., Rodel, B., Moroy, T., and Latchman, D. S. (1996) Biochem. J. 314, 439-443 [Medline] [Order article via Infotrieve]
  28. Dawson, S. J., Morris, P. J., and Latchman, D. S. (1996) J. Biol. Chem. 271, 11631-11633 [Abstract/Free Full Text]
  29. Milton, N. G. N., Bessis, A., Changeux, J. P., and Latchman, D. S. (1995) J. Biol. Chem. 270, 15143-15147 [Abstract/Free Full Text]
  30. Milton, N. G. N., Bessis, A., Changeux, J-P., and Latchman, D. S. (1996) Biochem. J. 317, 419-423 [Medline] [Order article via Infotrieve]
  31. Oyler, G. A., Higgins, G. A., Hart, R. A., Battenberg, E., Billinsley, M., Bloom, F. E., and Wilson, M. C. (1989) J. Cell Biol. 109, 3039-3052 [Abstract]
  32. Latchman, D. S. (1995) Eukaryotic Transcription Factors, Ed. 2, Academic Press, San Diego, CA
  33. Latchman, D. S. (1996) Int. J. Biochem. Cell Biol. 28, 965-974 [CrossRef][Medline] [Order article via Infotrieve]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.